Cutaneous ulcerations on hands and heels secondary to long-term hydroxyurea treatment

European Journal of Dermatology

Volumn 14, Issue 5, 2004, Pages 343-346

  Friedrich, Sarah ^a   Raff, Kerstin ^a   Landthaler, Michael ^a   Karrer, Sigrid ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Chronic myelocytic leukemia (CML); Cutaneous lesions; Hydroxyurea; Skin tumours

Indexed keywords

ACETYLSALICYLIC ACID; DIGITOXIN; FAMOTIDINE; HYDROXYUREA; IMATINIB;

ACTINIC KERATOSIS; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; ERYTHEMA; HAND DISEASE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEEL; HUMAN; HYPERPIGMENTATION; HYPOTENSION; LABORATORY DIAGNOSIS; LABORATORY TEST; LONG TERM CARE; MALE; PHYSICAL EXAMINATION; SKIN TUMOR; SKIN ULCER; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID; MALE; SKIN ULCER;

EID: 4544322687     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dressler WFC, Stein R. Über den hydroxylharnstoff. Justus Liebig's Ann Chem Pharm 1869; 150: 242-52.
2. Rosenthal F, Wislicki L, Kollek L. Über die beziehungen von schwersten blutgiften zu abbauprodukten des eiweisses: Ein beitrag zum entstehungsmechanismus der perniziösen anämie. Klin Wochenschr 1928; 7: 972-7.
3. Stock CC, Clarke DA, Philips FS, Barclay RK. Sarcoma 180 screening data. Cancer Res 1960; 20: 193-381.
4. Stearns B, Losee KA, Bernstein J. Hydroxyurea. A new type of potential antitumor agent. J Med Chem 1963; 6: 201.
5. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19: 1-0.
6. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SS, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. Investigators of the multicentre study of hydroxyurea in sickle cell anaemia. N Engl J Med 1995; 332: 1317-22.
7. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19(3 suppl. 9): 11.
8. Klem EB. Effects of antipsoriasis drugs and inhibitors of growth of epidermal cells in culture. J Invest Dermatol 1978; 70: 27-32.
9. Layton AM, Sheehan-Dare RA, Goodfield MJD, Cotterill JA. Hydroxyureo in the management of therapy resistant psoriasis. Br J Dermatol 1989; 121: 647-53.
10. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, et al. Hydroxyurea as on inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266: 801-5.
11. Lori F, Gallo RC. Hydroxyurea and AIDS: An old drug finds a new application? Retroviruses 1995; 11(10): 1149-51.
12. Montaner JS, Zala C, Conway B, Raboud J, Patenaude P, Rae S, et al. A pilot study of hydroxyurea among patients with advanced Human Immunodeficiency Virus (HIV) disease receiving chronic didanosine therapy. Canadian HIV trials network protocol 080. J Infect Diseases 1997; 175: 801-6.
13. Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol 1975; 111: 183-7.
14. Sigal M, Crickx B, Blanchet P, Perron J, Simony J, Belaich S. Lésions cutanées induites par l'utilisation au long cours de l'hydrohyurée. Ann Dermatol Venereol 1984; 111: 895-900.
15. Thomas L, Ferrier E, Moulin G. Dermatomyositis-like eruption complicating hydroxyurea therapy of chronic myelogenous leukemia. Report of a case and literature review. Eur J Dermatol 1992; 2: 492-5.
16. Papi M, Didona B, De Pità O, Abruzzese E, Stasi R, Papa G, et al. Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea. J Am Acad Dermatol 1993; 28: 485-6.
17. Stasi R, Cantonetti M, Abruzzese E, Papi M, Didona B, Cavalieri R, et al. Multiple skin tumors in long-term treatment with hydroxyurea. Eur J Haematol 1992; 48: 121-2.
18. Grange F, Couilliet D, Audhuy B, Krzisch S, Schlecht P, Guillaume JC. Kératoses multiples induites par l'hydroxyurée. Ann Dermatol Venereol 1995; 122: 16-8.
19. Senet P, Aractingi S, Porneuf M, Perrin P, Duterque M. Hydroxyurea-induced dermatomyositis-like eruption. Br J Dermatol 1995; 133: 455-9.
20. Richard M, Truchetet F, Friedel J, Leclech C, Heid E. Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J Am Acad Dermatol 1989; 21: 797-9.
21. Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori 1986; 72: 317-21.
22. Nguyen TV, Margolis DJ. Hydroxyurea and lower leg ulcers. Cutis 1993; 52: 217-9.
23. Best PJ, Daoud MS, Pittelkow MR, Pettit RM. Hydroyurea-induced leg ulceration in 14 patients. Annals of Int Med 1998; 128: 29-32.
24. Radaelli F, Calori R, Faccini P, Maiolo AT. Early cutaneous lesions secondary to hydroxyurea therapy. Am J Hematol 1998; 58: 82-3.
25. Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39: 372-4.
26. Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O'Brien S, Markowitz A, et al. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leukemia and Lymphoma 1999; 35(1-2): 109-18.
27. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1997; 36: 178-82.
28. Plucinski TM, Fager RS, Reddy GPV. Allosteric interaction of components of the reptilase complex is responsible for enzyme cross inhibition. Mol Pharmacol 1990; 38: 114-20.
29. Woofter JC, Anderson PC. Megaloblastic anemia in the management of severe psoriasis. W V Med J 1975; 71: 352-3.
30. Vassallo C, Passamonti F, Merante S, Ardigò M, Nolli G, Mangiacavalli S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Experimental Dermatol 2001; 26: 141-8.